Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest Treatments of Parkinson's Disease Stories

2012-07-15 18:20:20

BRUSSELS and ATLANTA, July 16, 2012 /PRNewswire/ -- UCB announced today that Neupro(®) (Rotigotine Transdermal System) is now available in U.S. pharmacies. Neupro(®) was approved by the U.S Food and Drug Administration in April to treat the signs and symptoms of early and advanced stage idiopathic Parkinson's disease and moderate-to-severe primary Restless Legs Syndrome. Neupro(®) improves motor function and activities of daily living in patients with PD and provides effective...

2012-06-21 02:26:00

AMSTERDAM, June 21, 2012 /PRNewswire/ -- uniQure, a leader in the field of human gene therapy, announced today the signing of a collaborative agreement with two leading neurology experts to develop further a gene therapy incorporating uniQure's GDNF (glial cell derived neurotrophic factor) gene for the treatment of Parkinson's disease. Professor Krystof Bankiewicz at the University of California, San Francisco (UCSF), a world expert in GDNF gene therapy, and Professor...

2012-06-06 02:24:40

SUNNYVALE, Calif., June 6, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing drug and diagnostic products for the treatment of Parkinson's disease and other nervous system disorders including Traumatic Brain Injury, today announced that it has been selected to participate in the National Investment Banking Association's 122nd Conference in New York City at Le Park Meridien Hotel June 7-8, 2012. Mr. Gerald Commissiong, Amarantus'...

2012-05-09 02:25:49

SUNNYVALE, Calif., May 9, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) for the treatment of Parkinson's disease and other nervous system disorders, today announced that it has been selected to participate in the Wall Street 1-2-1 Conference in Orlando, Florida at the Rosen Shingle Creek Resort May 8-11, 2012. Mr. Gerald Commissiong, Amarantus' President & CEO, will be a...

2012-05-01 02:31:31

SUNNYVALE, Calif., May 1, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) for the treatment of Parkinson's disease and other nervous system disorders, today announced that it has been selected to present in the Emerging Companies Showcase at the New York Biotechnology Association's 21st Annual Meeting on May 2nd, 2012 in New York City at the Marriott Marquis Hotel. Mr....

2012-04-26 06:26:07

ATLANTA, April 26, 2012 /PRNewswire/ -- Insights into the effects of Neupro(®) (rotigotine transdermal system) on common non-motor symptoms of Parkinson's disease (PD) were presented today at the 64th AAN Annual Meeting in New Orleans, LA. A post-hoc analysis of data from five, randomized, double-blind, placebo-controlled trials investigated the effect of rotigotine transdermal system on neuropsychiatric features and fatigue in patients with PD. Improvements were observed...

2012-04-02 18:20:20

BRUSSELS and ATLANTA, April 3, 2012 /PRNewswire/ -- regulated information--UCB announced today that the U.S. Food and Drug Administration (FDA) approved Neupro® (Rotigotine Transdermal System) for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson's disease (PD) and as a treatment for moderate-to-severe primary Restless Legs Syndrome (RLS). Neupro® was previously approved by the FDA for the signs and symptoms of early stage idiopathic PD. Neupro® is a...

2011-12-01 06:00:00

SAN DIEGO, Dec. 1, 2011 /PRNewswire/ -- Ceregene, Inc. reported today that it has completed enrollment in its Phase 2b trial of CERE-120, a gene therapy product expressing the neurturin (NRTN) gene for the treatment of Parkinson's disease. This Phase 2b study enrolled 51 patients at 11 medical centers throughout the United States. CERE-120 is comprised of an AAV vector intended to provide constant, sustained expression of neurturin (NRTN), a neurotrophic factor shown to...

2011-11-09 06:00:00

NESS ZIONA, Israel, November 9, 2011 /PRNewswire/ -- NeuroDerm [http://www.neuroderm.com ], Ltd. announced today the results of a Phase I/II safety and pharmacokinetic trial of ND0611, administered as an adjunct therapy to Sinemet(R), Sinemet(R) CR or Stalevo(R), in patients with advanced Parkinson's disease. ND0611 is a proprietary carbidopa liquid formula administered sub-cutaneously via a dermal patch to increase the bioavailability and efficacy of orally- administered...

2011-07-28 08:01:00

--Parkinson's Toolkit Now Available In iTunes App Store and Android Market-- MIAMI, July 28, 2011 /PRNewswire-USNewswire/ -- The National Parkinson Foundation (NPF) announced the launch of the first free smart phone application to improve diagnosis and treatment of Parkinson's disease (PD). The Parkinson's Toolkit is a mobile-enhanced website with a companion smart phone app available for download at toolkit.parkinson.org. "The National Parkinson Foundation is dedicated to providing...